Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xinpi Tongzhi Formula is a Traditional Chinese Medicine (TCM) herbal formulation developed by Xiyuan Hospital of the China Academy of Chinese Medical Sciences. It is currently being evaluated in clinical trials for its efficacy in improving the prognosis of patients with coronary artery disease, specifically those with coronary small vascular lesions who have undergone drug-coated balloon (DCB) dilatation. The formula is designed to be used as an adjunctive therapy to standard Western medical treatments, aiming to reduce the risk of major adverse cardiovascular events (MACE) and improve vascular healing. In the context of TCM theory, the formula likely addresses imbalances in the Heart and Spleen systems to promote blood circulation and resolve stasis, thereby preventing restenosis and improving clinical outcomes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xinpi Tongzhi Formula.